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The virulence properties of human immunodeficiency virus type 2 (HIV-2) are known to vary significantly
and to range from relative attenuation in certain individuals to high-level pathogenicity in others. These
differences in clinical manifestations may, at least in part, be determined by genetic differences among infecting
virus strains. Evaluation of the full spectrum of HIV-2 genetic diversity is thus a necessary first step towards
understanding its molecular epidemiology, natural history of infection, and biological diversity. In this study,
we have used nested PCR techniques to amplify viral sequences from the DNA of uncultured peripheral blood
mononuclear cells from 12 patients with HIV-2 seroreactivity. Sequence analysis of four nonoverlapping
genomic regions allowed a comprehensive analysis of HIV-2 phylogeny. The results revealed (i) the existence
of five distinct and roughly equidistant evolutionary lineages of HIV-2 which, by analogy with HIV-1, have been
termed sequence subtypes A to E; (ii) evidence for a mosaic HIV-2 genome, indicating that coinfection with
genetically divergent strains and recombination can occur in HIV-2-infected individuals; and (iii) evidence
supporting the conclusion that some of the HIV-2 subtypes may have arisen from independent introductions
of genetically diverse sooty mangabey viruses into the human population. Importantly, only a subset of HIV-2
strains replicated in culture: all subtype A viruses grew to high titers, but attempts to isolate representatives
of subtypes C, D, and E, as well as the majority of subtype B viruses, remained unsuccessful. Infection with all
five viral subtypes was detectable by commercially available serological (Western immunoblot) assays, despite
intersubtype sequence differences of up to 25% in the gag, pol, and env regions. These results indicate that the
genetic and biological diversity of HIV-2 is far greater than previously appreciated and suggest that there may
be subtype-specific differences in virus biology. Systematic natural history studies are needed to determine
whether this heterogeneity has clinical relevance and whether the various HIV-2 subtypes differ in their in vivo
pathogenicity.
Since the first discovery of human immunodeficiency virus
type 2 (HIV-2) in West Africa in the mid-1980s (6, 13), much
has been learned about the epidemiology, geographic distribu-
tion, and disease association of this second human immuno-
deficiency virus (for a review, see reference 61). HIV-2 sero-
prevalence and seroincidence rates have been determined (18,
73, 74, 77, 80, 94), and the spectrum of immunological and
clinical consequences of HIV-2 infection has been character-
ized (19, 20, 62, 67, 68, 92, 93). In addition, numerous virus
isolates have been obtained (10, 14, 25, 50, 52, 53, 81), and
their molecular and biological properties have been deter-
mined (7, 22, 28, 35, 38, 46, 54, 84, 86, 97). Results from these
studies indicate that the clinical manifestations of HIV-2
infection are generally similar to those of HIV-1, in that both
viruses can cause immunodeficiency and AIDS in infected
individuals (61). The two virus types also share structural,
genetic, and biological properties and are believed to cause
CD4 cell depletion by similar mechanisms (36, 61). Despite
these similarities, however, there is increasing evidence that
HIV-1 and HIV-2 differ in their natural history of infection
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and in vivo pathogenicity (18, 62, 72, 76). HIV-2-infected
individuals exhibit longer clinical latency periods (4, 24),
progress more slowly after onset of symptoms (62, 76), and, in
the clinically asymptomatic stage, appear to have a lower virus
burden than individuals infected with HIV-1 (83). In addition,
both vertical and horizontal transmission rates are significantly
lower for HIV-2 (5, 23, 45). Finally, HIV-2 is relatively
confined to West Africa, and its appearance in other geo-
graphic areas has generally reflected epidemiological links to
individuals of West African origin (18, 75).
Clinical and biological differences between the two human
AIDS viruses must be viewed in the context of their origins and
evolutionary histories. Nonpathogenic lentiviruses (simian im-
munodeficiency viruses [SIVs]) related to HIV-1 and HIV-2
have been identified in different Old World primate species,
and phylogenetic analyses of their sequences indicate that they
fall into five major lentivirus lineages (SIVcpz from chimpan-
zees, SIVSM from sooty mangabeys, SIVSYK from Sykes'
monkeys, SIVAGM from African green monkeys, and SIVMND
from mandrills; see reference 82 for a review). Representatives
of the two human viruses do not form independent lineages but
instead cluster with either the chimpanzee viruses (HIV-1) or
the sooty mangabey viruses (HIV-2) (42, 44). These phyloge-
netic relationships, along with epidemiological and virological
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data arguing for a simian origin of HIV (32, 42, 44, 64, 70),
have led to the conclusion that HIV-1 and HIV-2 are the result
of simian-to-human cross-species transmissions and represent
zoonotic infections of humans (66, 82). In light of these
findings, differences in HIV-1 and HIV-2 biology and natural
history should not be surprising. Rather, such differences
should be expected, given the fact that the predecessors of
HIV-1 and HIV-2 evolved in diverse primate hosts, probably
for long periods of time, before they entered the human
population.
Evaluation of the full spectrum of HIV-1 and HIV-2 genetic
diversity represents an important first step in the elucidation of
their biological heterogeneity and varying virulence properties.
Over the past several years, much effort has been focused on
characterizing the global diversity of HIV-1 (21, 31, 60, 65).
Extensive molecular epidemiological studies have shown that
HIV-1 strains fall into two major genetic clusters, which appear
to represent independent introductions of primate lentiviruses
into the human population (82). One cluster (group M)
comprises the vast majority of HIV-1 isolates (including all
those characterized during the first decade of HIV-1 research)
and can be further subdivided into eight distinct lineages on
the basis of equidistance in the env and gag regions (60, 65).
These lineages have been termed sequence subtypes A to H
(60, 65). The second cluster (group 0) was only recently
discovered and is thus far represented by only a small number
of viruses from Cameroon (34, 88). Viruses from all these
different lineages have been identified in AIDS patients, and
they are generally believed to exhibit similar biological and
pathogenic properties. This assumption, however, may be
premature, since systematic studies comparing their natural
history and in vivo pathogenicity have not yet been performed.
In comparison to HIV-1, HIV-2 genetic variation has ap-
peared to be more limited. Only two sequence subtypes are
currently identified in the database (65), which, by analogy to
HIV-1, have been termed A and B. The great majority of
characterized HIV-2 strains, including all initially reported
(prototypic) isolates (ROD, ST, BEN, ISY, etc.), cluster in
sequence subtype A. Subtype B viruses are less frequent, and
only three representatives have thus far been reported (D205,
GH-2, and UC-1) (7, 22, 46). Importantly, subtype classifica-
tion of HIV-2 is based almost exclusively on sequences derived
from tissue culture-amplified isolates. Arguing that such iso-
lates might represent only a subset of a larger, genetically more
complex group of viruses, we reported previously the charac-
terization of HIV-2 sequences obtained directly from uncul-
tured patient material (32). Using nested PCR techniques, we
amplified the env and pol regions of three unique viruses.
Phylogenetic analyses suggested that one of these (7312A) was
a recombinant of subtype A and B viruses. The two others,
both derived from individuals from whom virus isolation was
repeatedly unsuccessful, were quite distinct from all other
known HIV-2 strains. One (2238) was somewhat more closely
related to subtype B than to subtype A viruses, although highly
divergent from both; the other (FO784) was more closely
related to SIVs infecting sooty mangabeys (SIVsM) and ma-
caques (SIVMAC) than to viruses of human derivation. Al-
though these results provided evidence for the existence of
additional evolutionary lineages, definitive subtype classifica-
tion of F0784 and 2238 was not possible, primarily because of
the limited number of non-subtype A HIV-2 sequences in the
database (only 10 full-length HIV-2 sequences have thus far
been reported, 8 of which represent viruses that belong to
sequence subtype A [65]).
Following up on these earlier studies, we report here the
PCR amplification and sequence analysis of the gag, pol,
reverse transcriptase (RT), and env fragments from the periph-
eral blood of nine additional HIV-2-infected individuals. Anal-
yses of these new viruses, along with more extensive charac-
terization of the previously reported 2238, F0784, and 7312A
strains (32), have now allowed a comprehensive study of HIV-2
phylogeny and have revealed the existence of five major
lineages, which we term HIV-2 sequence subtypes A to E.
Importantly, viruses representing the new sequence subtypes
(C to E) were all derived from individuals from whom virus
isolation was repeatedly unsuccessful. These results thus indi-
cate that analyses of viruses that grow readily in tissue culture
may substantially underrepresent viral strains present in cer-
tain human populations.
MATERLILS AND METHODS
Subjects. Table 1 summarizes available demographic and
clinical information for all study participants. Patient histories
are described in greater detail below except for subjects 2238,
F0784, 7312A, and PA, which have been reported previously
(32, 43).
Subjects ON, JA, FT, and FA were identified to be HIV-2
infected at the University of Ghana Medical Center (Korle Bu
Hospital) in Accra. Three of them (ON, JA, and FA) were
in-patients and suffered from end-stage AIDS. Patient ON was
a 48-year-old fisherman who was hospitalized because of
weakness, fever, weight loss, chronic diarrhea, and oral thrush.
As risk factors for infection, he reported frequent encounters
with prostitutes in Ghana as well as in Cote d'Ivoire. Subject
FT was his wife, who was also infected with HIV-2 but
clinically asymptomatic. Patient JA was a 27-year-old female
who suffered from chronic diarrhea, severe weight loss, ane-
mia, and alopecia. She was married to a Nigerian man and had
lived in Lagos, Nigeria, for 5 years prior to returning to Ghana
because of onset of illness. Patient FA was a 36-year-old
female who was admitted to the hospital because of pulmonary
tuberculosis. She had lived in both Ghana and Cote d'Ivoire
for several years and suffered from fever, severe weight loss,
diarrhea, and AIDS dementia complex.
Subjects 7810A, 7924A, 60667K, and 60415K were identified
as HIV-2 seropositive in the United States. All of them were
heterosexual West African nationals living in the Washington,
D.C., area, where they sought medical care for sexually trans-
mitted diseases (STDs). Moreover, all of them originated from
urban areas of West Africa and had traveled extensively before
coming to the United States. Subject 7810A was a 31-year-old
student from Cote d'Ivoire. He was asymptomatic at the time
of presentation, with normal CD4 counts, and a heterosexual
partner of 3 years was found to be HIV seronegative. Subject
7924A was a 48-year-old teacher from Guinea Bissau who was
hospitalized because of severe weight loss and chronic diar-
rhea. Clinical evaluation revealed reduced CD4 counts (50
cells per mm3) and infection with Shigella flexneri and Giardia
lamblia. Subject 60667K was a 37-year-old female from Sierra
Leone who presented with low CD4 counts (361 cells/mm3) but
was otherwise asymptomatic. She had two teenage children,
who were both HIV seronegative. Subject 60415K was a
37-year-old asymptomatic man from urban Senegal who was
married to an American intravenous drug abuser.
Serology. Patients were identified as HIV-2 seroreactive (or
HIV dually reactive) by collaborating investigators. All sero-
logical results were confirmed with commercially available
Western immunoblot kits (NEW LAV-BLOT I/II and PEPTI-
LAV 1-2 from Pasteur Diagnostics, Marnes-la-Coquette,
France; HIV-1 and HIV-2 Western Blots from Cambridge
Biotech, Worcester, Mass.). Assays were performed and re-
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TABLE 1. Demographic and clinical characteristics of the study participantsa
Subject Age (yr) Sex Origin Disease status CD4 count Blood sample date(s) Serology(cells/mm3) (mo/yr)
2238 47 Male Liberia (rural) Asymptomatic N/A 1/89* HIV-2
5/89
F0784 46 Male Liberia (rural) Asymptomatic N/A 11/89 HIV-2
3/90*
ON 48 Male Ghana (urban) AIDS N/A 5/90* Dual HIV
FT N/A Female Ghana (urban) Asymptomatic N/A 5/90* HIV-2
JA 27 Female Ghana (urban) AIDS N/A 5/90* Dual HIV
FA 36 Female Ghana (urban) AIDS N/A 5/90* HIV-2
7312A 32 Male C6te d'Ivoire (urban) Lymphadenopathy 587 9/90 Dual HIV
6/91*
7810A 31 Male C6te d'Ivoire (urban) Asymptomatic 769 5/93* HIV-2
7924A 48 Male Guinea-Bissau (urban) AIDS 50 7/93* Dual HIV
60415K 34 Male Senegal (urban) Asymptomatic 698 7/93* HIV-2
60667K 37 Female Sierra Leone (urban) Asymptomatic 361 4/93* Dual HIV
PA 35 Male Sierra Leone (rural) Asymptomatic >500 3/91* HIV-2
10/91
Informed consent was obtained from all study participants prior to blood collection. Patient histories are described in Materials and Methods except for subjects
2238, F0784, 7312A, and PA, which have been reported previously (32, 43). Asterisks denote serum or plasma samples used for serological confirmation (compare Fig.
4). N/A, information not available.
sults were scored according to the manufacturer's recommen-
dations.
Tissue culture. Peripheral blood from subjects ON, FT, JA,
and FA was collected in Ghana and transported to the United
States within 48 h of phlebotomy. Blood samples from 7810A,
7924A, 60415K, 60667K, and PA were obtained in the United
States. Blood was processed and cultured in four different
laboratories (Table 2): 7810A, 7924A, 60415K and 60667K at
the University of Alabama at Birmingham (UAB); ON, FT,
JA, and FA at the National Cancer Institute (NCI, Bethesda,
Md.); and PA at the University of California, Los Angeles
(UCLA, Los Angeles, Calif.) and the Aaron Diamond AIDS
Research Center (ADARC, New York, N.Y.). Culture at-
tempts from subjects 2238, F0784, and 7312A (performed at
UAB) have been reported previously (32); the results are
included in Table 2 for comparison.
Plasma was separated by low-speed centrifugation, and
peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll density centrifugation as described before (12, 15, 78). A
portion of the cells was used for DNA extraction (see below),
and the remainder was cultured by different isolation ap-
proaches (see Table 2). All PBMC samples were cocultured
with phytohemagglutinin-stimulated normal donor lympho-
cytes according to standard protocols (12, 15, 78). For four
patients, this was done on more than one occasion (Table 2). In
some instances, virus isolation attempts also included plasma
cultures (78) or cocultivation of patient PBMCs with immor-
talized T-cell lines (CEM, H9, and Molt4 clone 8), normal
donor macrophages (prepared by plastic adherence and grown
in the presence of recombinant granulocyte-macrophage or
macrophage colony-stimulating factor [57]), and rhesus ma-
caque PBMCs (10). On two occasions, lymphocyte prepara-
tions from patient PA were fractionated prior to culture to
remove CD8+ cells. This was done by causing patient PBMCs
to adhere to plastic dishes coated with CD8-specific antibodies
as described before (96). All cultures were maintained for
several weeks, inspected for the appearance of virus-induced
syncytia, and monitored for supernatant RT activity or the
presence of p24/p27 antigen (12, 15, 78). Cultures were
considered positive when RT activity or p24/p27 antigen was
detectable on two consecutive occasions.
PCR. High-molecular-weight DNA was extracted from un-
TABLE 2. Attempts to isolate virus from the peripheral blood of 12 HIV-2 seropositive individualsa
Cocultivation of patient PBMCs with:
No. of independent Plasma CD8 depletion ofSubject Laboratory isolation attempts Normal donor Normal donor Immortalized Rhesus macaque culture patient PBMCs
PBMCs macrophages T-cell lines PBMCs
2238* UAB 2 - ND - ND - ND
F0784* UAB 2 - - - ND - ND
ON NCI 1 - ND ND ND ND ND
FT NCI 1 - ND ND ND ND ND
JA NCI 1 - ND ND ND ND ND
FA NCI 1 + ND + ND ND ND
7312A* UAB 3 + ND + ND - ND
7810A UAB 1 - ND ND ND ND ND
7924A UAB 1 + ND ND ND ND ND
60415K UAB 1 + - ND ND ND ND
60667K UAB 1 + ND ND ND ND ND
PA UCLA and ADARC 7
Vvirus isolation was performed at UAB, NCI, UCLA, and ADARC as described in Materials and Methods. Results for subjects 2238, F0784, and 7312A (indicated
by asterisks) have been reported previously (32). +, virus-positive culture; -, virus-negative culture; ND, cultures not performed because of lack of patient material.
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TABLE 3. Nested PCR primer pairs used to amplify HIV-2 subgenomic fragments from primary PBMC DNAa
Primer pair Nucleotide sequence Location Reaction Fragment Genomicconditions' size (bp) region
Outer pair
LTR A 5'-CTGAGACTGCAGGGACTTTCCAGAAGGG-3' 9379-9406 1 min, 94°C; 1 min, 45°C; 140 LTR (U3/R)
LTR B* 5'-AAGCAGAAAGGGTCCTAACAGACCAGGGT-3' 9739-9767 1 min, 72°C; 30 cycles
Inner pair
LTR C 5'-AGGCTGGCAGATTGAGCCCTGGGAGGTTC-3' 9513-9541
LTR D* 5'-CCAGGCGGCGACTAGGAGAGATGGGAGCAC-3' 9682-9711
Outer pair
env A* 5'-GCTAGGGTTCTTGGGTTTTCTCGCGACAGCAGG-3' 7691-7723 1.5 min, 94°C; 1.5 min, 45°C; 453 env (gp4l)
env B* 5'-CAAGAGGCGTATCAGCTGGCGGATCAGGAA-3' 8415-8444 1.5 min, 55C; 35 cycles
Inner pair
env C 5'-GGGATACTGCAGCAACAGCAACAGCTGTTG-3' 7782-7811
env D 5'-GGGAGGGGAAGAGAATTCTGGCCTATA-3' 8265-8291
Outer pair
pol A* 5'-AATATACTAGTAGATTCACAATATGT-3' 3857-3882 1 min, 94°C; 1.5 min, 40°C; 708 pol (integrase)
pol B* 5'-CTGCCTTCTCTGAAATAGACCCGAAAA-3' 4723-4749 2 min, 70°C; 30 cycles
Inner pair
pol A* 5'-AATATACTAGTAGATTCACAATATGT-3' 3857-3882
pol D* 5'-CTTCTTTTAAAATTCATGCAATGAACTGCC-3' 4591-4620
Outer pair
gag A 5'-AGGTTACGGCCCGGCGGAAAGAAAA-3' 603-627 1 min, 94°C; 1 min, 40°C; 781 gag (p16/p28)
gag B 5'-CCTACTCCCTGACAGGCCGTCAGCATTTCTTC-3' 1581-1612 2 min, 72°C; 30 cycles
Inner pair
gag C 5'-AGTACATGTTAAAACATGTAGTATGGGC-3' 628-655
gag F 5'-CCTTAAGCTTTTGTAGAATCTATCTACATA-3' 1437-1466
Outer pair
RTC* 5'-ATGACAGGGGATCCCCCAATCAATATTTTTG-3' 2309-2339 1.5 min, 94°C; 1 min, 40°C; 995 pol (RT)
RT2 5'-GAAGTCCCAGTCTGGGATCCATGTCACTTGCCA-3' 3593-3526 2 min, 72°C; 30 cycles
Inner pair
RT3 5'-GAGGCATTAAAAGAGATCTGTGAAAAAATGG-3' 2474-2504
RT4 5'-TCCCCAAATGACTAGTGCTTCTTTTTCCTAT-3' 3500-3529
a Primer pairs were designed according to HIV/SIV consensus sequences (65); sequences are numbered according to the published sequence of HIV-2/ROD (35);
asterisks denote previously published primers (restriction enzymes sites are underlined) (3, 32).b Conditions used for both sets of primers.
cultured patient PBMCs under PCR cleanroom conditions and
subjected to nested PCR amplifications with primer pairs
designed according to HIV-2/SIVSM/SIVMAC consensus se-
quences (65). All primer sequences and amplification condi-
tions are described in Table 3, except for a previously reported
set of HIV-1 primers used to exclude HIV-1 infection in
individuals with dual HIV seroreactivity (HIV-1 LTR I-IV [3]).
PCRs were carried out in a total volume of 100 RI, containing
1 Rg of genomic DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
20 pmol of each primer, 200 ,uM each of the four deoxynucleo-
side triphosphates (dNTPs), 1.5 mM MgCl2, 0.01% (wt/vol)
gelatin, and 2.5 U of Taq polymerase. Samples were overlaid
with 100 ,ul of mineral oil to prevent evaporation and then
subjected to 30 to 35 amplification cycles, as indicated in Table
3. Second-round PCR products were visualized by agarose gel
electrophoresis, isolated from a preparative gel, purified with
GeneClean (Bio 101 Inc., La Jolla, Calif.), and subcloned into
M13mpl8 and 19 by using restriction enzyme sites (env frag-
ments) or pCR vectors (Invitrogen, San Diego, Calif.) by T/A
overhang (pol fragments were subcloned into pCR1000; gag
and RT fragments were subcloned into pCRII).
DNA sequence analysis. Recombinant clones containing
HIV-2 fragments were sequenced manually by the dideoxy-
nucleotide chain termination method (Sequenase Kit; US Bio-
chemicals, Cleveland, Ohio) or on an automated DNA se-
quenator (model 373A; Applied Biosystems, Inc.) using cycle
sequencing and dye terminator methods. Generally, only one
clone per amplification product was sequenced except for env
and pol fragments from subjects ON, JA, and FA and gag and
RT fragments from subject F0784, for which multiple se-
quences were obtained (data not shown). Importantly, 7312A
gag, pol, and env sequences were not derived from PCR
products but from a replication-competent provirus cloned
from a short-term-infected PBMC culture (37). This was done
to examine previously noted discordant phylogenetic positions
of 7312A env and pol sequences (32) in the context of a single
viral genome. Sequence analysis was performed with PC/Gene
(IntelliGenetics Inc., Mountain View, Calif.), EuGene (Baylor
College of Medicine, Houston, Tex.), MASE (26), and DOTS
(55).
Phylogenetic analysis. The phylogenetic relationships of the
newly identified viruses to previously published HIV-2/SIVSM/
SIVmAc strains (65) were estimated from comparisons of their
nucleotide sequences. Sequences were aligned by using
CLUSTAL (39, 40) with minor manual adjustments, bearing in
mind their predicted protein sequences. Pairwise evolutionary
distances were estimated by using Kimura's two-parameter
method (equation 4.14 in reference 49) to correct for super-
imposed substitutions. Sites at which there was a gap in any of
the aligned sequences were excluded from all comparisons.
Phylogenetic relationships were computed from these dis-
tances by the neighbor-joining method (79). The repeatability
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FIG. 1. Location of HIV-2 sequences amplified from uncultured patient PBMCs. Sequences derived from the gag (781 bp), pol (RT region, 995
bp; integrase [int] region, 708 bp), and env (453 bp) regions were used for phylogenetic analyses; the LTR (140 bp) region was amplified for
diagnostic purposes only.
of the branching orders obtained was estimated by the boot-
strap approach (27). These methods were implemented with
CLUSTAL V (39). Phylogenetic relationships were also ana-
lyzed from predicted protein sequences (using Kimura's em-
pirical method to estimate distances; equation 4.8 in reference
49) and by using alternative approaches to phylogenetic recon-
struction, such as the dynamically weighted parsimony method
(95).
Nucleotide sequence accession numbers. All sequences were
submitted to GenBank and the Los Alamos Database. Clone
designations and GenBank accession numbers are listed below
(clone designations contain patient identifier, genomic region,
and clone number): 60415Kgag.8, L33076; 2238gag.1, L33077;
60667Kgag.1, L33078; 7312Agag.JK, L33079; 781OAgag.2, L33
080; 7924Agag.1, L33081; FAgag.2, L33082; FO784gag.10/3,
L33083; FTgag.1, L33084; JAgag.1, L33085; ONgag.18, L33086;
PAgag.1, L33087; 7312Apol.JK, L33088; FApol.1, L33089;
JApol.9, L33090; ONpol.6, L33091; 7312ART.JK, L33092;
PART.6, L33093; 7312Aenv.JK, L33094; FAenv.15, L33095; JA
env.12, L33096; and ONenv.12, L33097.
RESULTS
Demographic and clinical characteristics of the study par-
ticipants. The purpose of this study was to determine the
extent of HIV-2 genetic and biological heterogeneity as it
exists in infected individuals in vivo. To this end, we collected
blood samples from 12 HIV-2 seropositive individuals and
characterized their viruses by PCR amplification of viral
sequences directly from uncultured PBMC DNA. Although
the samples were not obtained as part of a systematic molec-
ular epidemiological survey, they were nevertheless analyzed in
a systematic fashion; that is, molecular characterization was
performed on all specimens with serological indication of
HIV-2 infection regardless of whether simultaneous attempts
to isolate virus were successful. Moreover, viruses were ana-
lyzed from a geographically diverse group of individuals (Table
1). The 12 subjects originated from six different West African
countries and represented urban as well as rural populations.
Finally, virus was characterized from individuals at different
stages of disease. Seven subjects were healthy at the time of
blood collection, while five others had symptoms ranging from
generalized persistent lymphadenopathy to end-stage AIDS.
The viruses reported in this study are thus representative of a
broad spectrum of HIV-2 infections and are not biased with
respect to in vitro replication potential, geographic origin, or
disease association.
Virus isolation studies. Virus isolation was performed in
four different laboratories (UAB, NCI, UCLA, and ADARC)
by techniques routinely employed to culture HIV-1 from
individuals at all stages of infection (12, 15, 78). Table 2
summarizes the different strategies used as well as the number
of independent isolation attempts (culture attempts for sub-
jects 2238, F0784, and 7312A have been reported previously,
but the results are included in Table 2 for comparison [32]). All
patient PBMCs were cocultured with phytohemagglutinin-
stimulated normal donor lymphocytes according to standard
protocols (12, 15, 78). In some cases, isolation attempts also
included cocultivation with normal donor macrophages (57)
and immortalized T-cell lines (52), as well as plasma cultures
(78) (Table 2). Using these approaches, virus was successfully
recovered from primary PBMC cultures of subjects FA, 7924A,
60415K, and 60667K Moreover, virus from subject FA repli-
cated to high titers and was transmissible to the immortalized
T-cell line CEM. By contrast, virus culture from blood samples
of subjects ON, FI, JA, 7810A, and PA remained unsuccessful.
This was the case despite active cell replication, excellent cell
viability, and, in some cases, confirmation of HIV-2 viral
sequences in short-term-cultured PBMC DNA by PCR ampli-
fication.
One of the subjects from whom virus isolation was repeat-
edly unsuccessful was patient PA. This immigrant from rural
Sierra Leone was identified as HIV-2 seropositive following
clinical evaluation for kidney transplantation because of end-
stage obstructive uropathy (43). Although the source of trans-
mission remained unknown, patient history revealed that sub-
ject PA had likely acquired his HIV-2 infection some 20 years
ago, prior to his move to the United States (43). Because the
patient underwent weekly dialysis at a Los Angeles hospital,
blood samples were frequently available and did not require
long transportation times (blood was usually hand carried to
the laboratory). Thus, additional isolation strategies were
pursued. These included multiple cocultivation attempts with
normal donor lymphocytes (using up to 107 patient PBMCs per
individual culture), normal donor macrophages, or rhesus
macaque PBMCs, as well as the analysis of viral growth
following stimulation of PBMC cultures with tumor necrosis
factor alpha or granulocyte-macrophage colony-stimulating
factor. Moreover, patient PBMCs were fractionated on two
different occasions to deplete CD8+ cells. This method has
been shown to increase isolation efficiencies of HIV-1 by
removing cells that produce a factor(s) that suppresses viral
replication (91). Between 1989 and 1993, blood was obtained
from subject PA on seven independent occasions. Despite
these intensive efforts, attempts to isolate virus from subject
PA remained unsuccessful.
PCR amplification of HIV-2 sequences from primary PBMC
DNA. As an alternative to virus culture, nested PCR was used
to characterize viral sequences directly in uncultured patient
materials. In a first step, PBMC DNAs were amplified with
long terminal repeat (LTR) primers known to detect HIV-2
sequences with high sensitivity and specificity (32, 37). Using
this "diagnostic" primer set, PCR products were amplified
from all PBMC specimens, confirming HIV-2 infection in all
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gag (pl16/p28) p16 *4~p28
CONS aNeLDrFGLaESLLesKEGCqkIl1sVLaPlVPTGSENLKSL?NtvcViwCiHAEEKvK?TEeAKq ivq?RHLvaeTgtaekMP ?t srPTAPpSgrggNyPVQq? ?gGNYvH
FA.------------IT--N .0-------F.-----L-----D----RKL----------N------S---F----TG----
60415K.-----------R--T--D.-------F.---A------ --G.------------S.----- --. --T
7924A.-----------R-I--D- --------F.---V------D----K----------.. N.------K---- .---T
ON V------R-----H---T---------F----Y-L---0--D---KMA-. S---VDA. .. --T-A-----------VA.-.VA-
FT V------T-----H---T-------- F----F-L---Q---D---K-A-.S---VDA...--V-A--KS .------------VA---
JA V---------- H---T----------F----VY-L-----D----K-A-. S--AVN-... --T-A------ .--.---- VA---
#7312A . .------N.-------T----M------F.-----L---K---D---KLA-.S---VD-...--T-TADK-A-TS----------VA---
7810A .------T--G .--H---TA---------F----VY-L-----D----K-A-. S--A-N-......--A--K - .----------VA---
60667K V---E.----N--G.---H---A--E--------F.----Y-L--G----D .--K-A-.-----GN-......----A .--S--G. ------ IA---S-
F0784 .--------N--------------Y.-----L-----D--G.---------V .--D---S.-----D--R.-----V----
2238 .----A.----T-----T--E.-------Y--T.---L---Q---H---RNEV-E.---A---KN.---A.----S--GR------VA---
PA -R.-------N----HR--T--E--M.------F-A---VY-L--AV---D .--KH--QH----GGK-T--L-PQ .-----G.----- I-N----
FA V-- --. 1 ----0.L-- - - -A---I-- -0 .-- -- -A---
60415K I-- -- - - -- -E--V---I-- -D -.
7924A V-- - -- -- -V-- --VA--I ..-- -E--- --F-A---
JA--------------------------E-----------Q---V--0---D-------E-E----A---
#7312A V------------------------E----V.-------Q---V-------D .------E-----G-S-
7810A.0.---- -D- -- - - -E.--- -- - - -Q---S .0.--- - -E .- -A---
60667K.-----------EN.----------------IE.------E--Q---S---M.-----------E .---C-A---
2238 H.-- - - - -T .-- -L.-- -EH--V.-- --D .- -E .- -A---
PA S.------------------------E.-----------V---RGQ-. --QG--D-S------P -E---N
CONS ?PVGnIYrRWIQ1GLQKCVRmYNPtnILDvkQGPKEpFQS 253
FA I------V-I.-------V------5 261
60415K V-------I----------I .----- 260
7924A V-- -I-- -- - -- 5 260
ON V-- -I-- -S-- - 255
FT V-- -I-- - -- - 255
JA V----------------I-E . ---- 255
7312A I-- -- - 255
7810A I-- -I . --- 255
60667K V-------I---------I.-----N 255
F0784 I----------------I.----T-- 260
2238 V-- 260
PA I---0 ...5--------------- 260
RT (reverse transcriptase)
CONS keGQLEeAPPTNPYNTPTFAIkkkDkNKWRmLIDFRELNkVTQDFTEvqlgiPhpaglAkkrRItvlDvGDAYFSI PLde?FRqYTAFTLPsvNNaEPgKRYiYKVlPQGW
#7312A .- -S-- -E . --- -WPE .--- -I-- -V---PD . .-- -I.--
* F0784 R--------------S--------------V.-----R ..---------KE.---T-----R--------
PA ----R--------R----S--------A----------KEMEQ----I----V---PE.-----I-----Q-------
CONS KGSpaIfqytmR?vLePFRkANpDvilidTMD5j LiASDRtdLEHDrVV1Q1KELLN??GFStPeEKFQKDPPfqWMGyELWPtkWKLQkiqLPqke?WTVNdIQKLVGVL
#7312A------S--K--D---R--N--TI f-- V-- S----K--S- ON--D ------------ K.-----I-ER-V-------
*F0784 .-------NI.-----S--T f-I- ------ K.------OL--L.------YH ..--------E---R-D ---.---
PA
---
V--E
---Q------S--L-- --L--G-N-SMT----M-V---DM--NL----0---RE--LK----L-Y-K .----E--E--R-------I-
CONS NAQyGKklrIGtlEVWEAAlEkIseE?YEklAvKqnWYHQ?iKG?KKttgrLhQK 319#7312A .---LF.---R-I----K-----------MQ----G.--S--K-GV-- Q--NLA---T---O-N-V.---Y--V.-----I----- 331
* F0784 . ..-----------K.----------Y.-------C----S .----V-D.--S----0 .----Y ...---------- 331
PA
---V-----N--K ..---------S----A-----G---R--R-EEN.---L-N.---S.--GDR.----FPQ . .5------S--- 331
pol (RNase H/integrase) RNase H *j~integrase
+ +
CONS MGIvagqPtEsEsrlVnqI IEeMIKKeaiYV H giGgEvDHLVSQgIRQVLFLekIEPAQEEHeKYHsnvKeLvhKFglP?lVArQIVntCdkcqqKGEaiHGQ
FA ----V.----N-I.0------- ------------ R--------I---T----I-Q------AQ------
ON ---I.----T--PI--K------- ---L----------------- G------I-Q---K----S------V
JA ---I.----T--PI--K------- -----L-- ---------------- .-----IHS---K----S.------V-
#7312A .------T--PI--K----------L- ----------------G------I-Q---K----S------V
* F0784 I-------K.---------I.0.---------------I----F.---K----ID.---HR.----
*2238 L--I.----T--P---R----L-R---V-I- -- -------------RF---A---T----I-N---K.----HV------
CONS vNaelGtWQMDcTHLEGKii IVAVHVaSGFI EAEVIPqEtGRQTALFLLKLAsRWPiTHLHTDNGaNFtSqeVKMvAWW?gIEqtFgVPYNPQSQgVVEAMNHHLKnQIdR
FA ----I V--V - - - -K----KSE ..--- - - - - - - -S-- -I-- - -5-----S
ON
------------------------
--
R------0-D----V----------------
JA -- ---------V----------- ------------D----V---R--------------
#7312A -----------V---------------------------D---- V----------------
* 2238
---D0 .-------V.-----------------A--------------V-V-H--------------
CONS iReQAns?ETiVL 232
FA ----TI.--- 235
ON --D--V-L--V- 235
JA
--D--V-I--V- 235
#7312A --D--V-I--V- 235
*F0784 --D----V.--- 235
*2238
.----TN .--- 235
env (gp4l) + +extracellular
CONS DVKQERLVGKLtVAEYkQlNWCFVCTVwNstdnmWeEk?eaI?EeiQENYLKNwvgFA .N-----M------A-------------V----------- Q--QQIRY---SES--Q------------
ON.------------------L-----------ETIE.-----Q--A--Q--D----Q.-----------Q--
JA-------------------L-----------ET-H-N-Q.---Q--Q--NY-D----Q-----------Q-0---#7312A . N.---M-------A-----------------V--0----D--0--KOIRD----SES--Q------------
*F0784 ....-------------------------E---ST.--------RQ-D.----0-----------N--I---
* 2238 . N .M--------------K----------V
---NQO-E-Q .---Q--KQIA---D---E---Q------------
domain
-<+ membrane spanning dormain
CONS WfDltsWikYIqyGvyivvgvi?LRiviYivQmLarlRkG 147
FA
----V-------IVA---I--V----S---R- 151
ON ---F---MAHLRL-L-V-A-I-V---N--M----- 151
JA ---F---NMA--KL-L-V-A-L-V .----I----K--- 151#7312A ----A--V.-------IVA--VI--V---IG---R- 151
*F0784 . .--------F----I-L---I--V .---K-S-- 151
* 2238 -L-----V---YL-F---A---V---A--V--M----- 151
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study subjects. By contrast, diagnostic HIV-1 LTR primers (3)
failed to amplify viral sequences, excluding simultaneous coin-
fection with HIV-1 in individuals with dual seroreactivity
(Table 1).
Nested PCR techniques were then used to derive larger
genomic regions for sequence determinations and phyloge-
netic studies. Four independent and nonoverlapping regions
were amplified (Fig. 1), two of which (a 451-bp env gp4l and a
708-bp pol integrase fragment) were chosen to allow compar-
ison with previously reported F0784 and 2238 sequences (32).
The other two, a 781-bp gag (pl6/p27) and a 995-bp pol(RT)
fragment, were selected to obtain additional sequences for a
more comprehensive phylogenetic analysis. By using the prim-
ers and conditions summarized in Table 3, all 12 PBMC
specimens were amplified in at least one of the four targeted
regions (because of lack of patient material, not all PBMC
DNAs could be amplified with all primer pairs). There were
only three instances in which primer pairs failed to amplify the
corresponding HIV-2 fragment despite repeated attempts and
various amplification conditions. These involved env and pol
(integrase) regions from subjects PA and FT and the pol (RT)
region from subject 2238.
Figure 2 depicts alignments of deduced amino acid se-
quences from available PCR fragments. Only sequences de-
rived from the 12 study subjects are shown in comparison to
the HIV-2/SIVsM/SIVmAc consensus sequence obtained from
the database (65). Previously reported env and pol sequences
from 2238 and F0784 as well as RT sequences from F0784 are
indicated by asterisks (32). Most sequences were derived from
single PCR clones except for env, pol, and RT amplification
products for ON, JA, FA, and F0784, for which multiple
clones were sequenced (not shown). In the latter cases, the
predominant clone which also contained an uninterrupted
open reading frame was chosen for comparison (Fig. 2 and 3).
Finally, all 7312A sequences were derived from a full-length
proviral genome cloned as a recombinant lambda phage from
short-term-cultured PBMC DNA (37). This was done to
examine the previously noted discordant phylogenetic relation-
ships of 7312A env andpol sequences in the context of a single
genetic unit.
Inspection of the deduced protein sequences indicated
conserved as well as variable protein domains (Fig. 2). As
expected, regions of known protein function were highly
conserved. These included the pl6/p27 cleavage site in the gag
precursor (85), the WVPAHKGI/LGGN region in the RNase
H domain (17), and the catalytic YMDD domain in the RT
(51, 90). Also conserved was the spacing of histidine, cysteine,
aspartic acid, and glutamic acid residues (HHCC and D,
D-35-E motifs), known to be essential for integrase function (9,
89), as well as two cysteine residues in the exterior portion of
gp4l which are believed to form an apical loop (30). Finally,
there were no length differences except in the gag region
(flanking the pl6/p26 cleavage site), where a subset of viruses
(ON, FT, JA, 7312A, 7810A, and 60667K) had the same codon
deletions relative to the consensus sequence.
Phylogenetic analyses. To determine the evolutionary rela-
tionships of the newly identified HIV-2 strains to previously
reported HIV-2 and SIVsM/SIVmAc isolates, phylogenetic
trees were constructed from the PCR-derived gag, pol (inte-
grase and RT), and env sequences. As shown in Fig. 3, these
analyses revealed five distinct phylogenetic lineages, or se-
quence subtypes, of HIV-2. Two of these corresponded to the
previously defined subtypes A and B, while three others
represented new subtypes of HIV-2. Importantly, the grouping
of viruses within the different lineages was consistent among
trees from all four genomic regions; that is, viruses that
belonged to a particular lineage in gag (Fig. 3A) also clustered
within the same lineage in pol (Fig. 3B and C) and env (Fig.
3D). As noted previously (32), there was only one clear
exception: 7312A clustered in different lineages depending on
which parts of its genome were analyzed. In phylogenetic trees
derived from gag and pol (RT and integrase) sequences, it
clustered with subtype B viruses. However, in trees constructed
from env sequences, it clearly grouped within subtype A. Since
both PCR-derived (32) and proviral sequences (this study)
exhibited the same discordant branching order, we concluded
that 7312A contains a mosaic genome generated by recombi-
nation of subtype A and B viruses.
Three of the newly characterized viruses (FA, 60415K, and
7942A) fell within the group that is known as subtype A. This
group, which contained the greatest number of viruses, was
clearly defined regardless of whether env, pol, RT, or gag
sequences were compared and occurred in 100% of bootstraps
in all four trees. Analysis of the increased number of subtype A
viruses also revealed an additional level of phylogenetic struc-
ture within this group, i.e., two distinct subclusters became
apparent in three of the four trees. One subset of viruses,
including BEN, D194, MVP-15132, and GH1, consistently
grouped separately from other subtype A strains. The other
viruses, represented by ROD, ISY, ST, CAM2, and NIHz, also
formed a monophyletic group in the env, pol (RT), and gag
trees but not in thepol (integrase) tree. Interestingly, one virus
(FA) for which three of the four regions were sequenced fell
into both subclusters. In the gag and pol (integrase) regions,
FA grouped with BEN, GH1, D194, and MVP-15132, but in
the env region, it grouped with ROD, ST, NIHz, ISY, and
CAM2. These discordant relationships were supported by high
bootstrap values and suggested a second example of a mosaic
genome, this time involving recombination of divergent viruses
from the same sequence subtype.
Five other newly characterized strains (ON, FT, JA, 7810A,
and 60667K) clustered with D205 and UC1 in what has been
termed subtype B. Again, this cluster emerged with high
bootstrap values in trees from all four genomic regions. Two of
the new viruses (ON and FT) were particularly closely related,
differing by only 4% in their PCR-derived gag region. Since
subjects ON and FT were husband and wife, we deduce that
one infected the other by heterosexual transmission.
The three other viruses (2238 and F0784 from Liberia and
PA from Sierra Leone) each defined a new lineage, and thus a
FIG. 2. Alignment of partial gag (pl6/p28), pol (RT and RNase H/integrase region), and env (gp4l region) protein sequences from 12
independent HIV-2 strains. Nucleotide sequences were determined from PCR amplification products (cloned into plasmid or M13 vectors),
translated, aligned, and compared with the HIV-2/SIVsM/SIVmAc consensus sequence from the database (65). Dashes denote sequence identity
with the consensus sequence, and dots represent gaps introduced to optimize the alignments. Capital letters in the consensus sequence indicate
sequence identity among all HIV-2 strains in the database. Lowercase letters and question marks indicate sites at which >50 or <50% of viruses
have the same amino acid residue,, respectively. Boxed amino acid residues and arrows above the consensus sequence indicate domains known to
be important for protein function. The p16/p26 gag precursor cleavage site as well as the beginning of the membrane-spanning domain in gp4l are
indicated. Asterisks denote previously published F0784 and 2238 sequences (32), and the symbol highlights 7312A sequences derived from a single,
replication-competent provirus (37).
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TABLE 4. Intra- and intercladal distances among sequence
subtypes of HIV-2 and HIV-la
HIV-2 % Nucleotide diversity HIV-1 % Nucleotide diversity
sub- sub-
type A B C D E type A B C D 0
A 8.8 A 9.3
B 17.3 10.0 B 12.8 4.0
C 18.2 18.6 N/A C 14.2 11.3 6.4
D 17.6 16.7 18.4 N/A D 13.6 8.0 10.8 6.5
E 24.6 23.9 23.4 24.6 N/A 0 30.9 31.6 31.9 31.5 10.5
a Average intra- and intercladal distances were calculated for the PCR-derived
HIV-2 gag sequences and compared with values obtained for corresponding
HIV-1 gag sequences from the database (65). Sequences were aligned by using
MASE (26), and distances were calculated by using DOTS (55). Intracladal
distances for HIV-2 subtypes C, D, and E are not available (N/A), since only
single representatives have thus far been identified.
new sequence subtype, of HIV-2. Virus 2238 consistently
appeared as a highly divergent strain, regardless of whether
gag, pol (integrase), or env fragments were analyzed (2238 is
not included in the pol-RT tree because this fragment could
not be amplified). In trees derived from pol (integrase) and,
particularly, env sequences, 2238 clustered relatively more
closely with subtype B than with subtype A viruses, but in the
gag tree, this situation was reversed. Since the latter grouping
was found in only a small number of bootstrap samples (33%),
this discrepancy was not significant. Moreover, branch lengths
for 2238 were very deep in trees from all three different
genomic regions. For these reasons, we defined 2238 as the
first member of a third lineage, termed sequence subtype C.
As reported previously, F0784 clustered with simian viruses
infecting sooty mangabeys and macaques rather than with
viruses of human derivation (32). This was the case in trees
from all four genomic regions, including the newly constructed
gag tree. The precise branching order within the F0784/SIV
cluster and the number of bootstrap replicates supporting it as
an independent group varied somewhat among the four differ-
ent trees. However, in the pol (RT) tree, which is derived from
the longest sequence and thus likely the most reliable, the
F0784/SIV cluster appeared in 98% of bootstraps. Interest-
ingly, the phylogenetic depth within the F0784/SIV cluster was
significantly greater than that within subtype A or B. Because
of this and the extensive divergence from subtype A, B, and C
viruses, we designated F0784 as a representative of a fourth
major subtype (subtype D; note that we use HIV-2 subtype
designations only for viruses of human derivation [82]).
The most divergent of all the HIV-2 strains was the virus
infecting subject PA. In the two genomic regions for which
sequence was available, PA formed the first lineage to branch
off from this group. Moreover, branches separating this point
from the main cluster were quite long, indicating an earlier
divergence of PA than of the other members of the HIV-2/
SIVsM/SIVmAc family. Because of this and its overall distance
from subtype A, B, C, and D viruses, we designated PA as a
representative of sequence subtype E.
Apart from the observation that subtype E (PA) branched
off first, there was no clear order of branching among the other
subtypes. Thus, subtypes A, B, and C clustered, to the exclu-
sion of the subtype D/SIV lineage, in two of the four trees (gag
and env) but not in the other two. Furthermore, the branches
outside these clusters were very short. These results are
consistent with a star phylogeny and suggest that subtypes A to
D diverged at roughly the same time. Very similar results were
obtained with the dynamically (asymmetrically) weighted par-
simony method, which produced trees that were virtually
identical to those shown in Fig. 3 in both topology and branch
lengths (data not shown).
Serological profile of sera from individuals infected with the
five different HIV-2 subtypes. From the phylogenetic analyses,
it was clear that the virus infecting subject PA represented the
most divergent HIV-2 strain identified thus far. In the PCR-
derived gag region, PA differed from all other HIV-2 strains in
25% of its nucleotide sequence, while members of HIV-2
subtypes A to D differed from each other by less than 19%
(Table 4). In the same genomic region, members of the highly
divergent group 0 differed from all other HIV-1 strains in 30%
of their nucleotide sequence, while viruses of HIV-1 subtypes
A to D differed by less than 14% (Table 4). Since subgroup 0
infections, because of their genetic distance, are not detected
by all commercially available serological assays (59), we
wanted to know whether this was also the case for the
divergent subtypes of HIV-2. Serum (or plasma) samples from
all study subjects were thus analyzed side by side with three
commercially available and widely used confirmatory tests (the
Pasteur NEW LAV-BLOT II and PEPTI-LAV 1-2 assays, as
well as the Cambridge Biotech HIV-2 Western blot kits). The
results revealed comparable serological profiles for all samples
(Figure 4 illustrates results obtained with the Cambridge
Biotech HIV-2 Western blot kit). Most sera, including those of
F0784 (subtype D) and PA (subtype E), reacted strongly with
all HIV-2 antigens. Weak reaction with the major capsid
protein p26 was observed with three sera (including 2238), but
this did not affect their scoring as HIV-2 antibody positive. In
addition, all sera reacted strongly in the PEPTI-LAV 1-2 assay,
indicating sufficient cross-reactivity even with this peptide-
based antigen (data not shown). Finally, cross-reactivity with
HIV-1 antigens was also observed (Table 1). However, this
dual seroreactivity was not correlated with any particular
subtype. Taken together, these results indicate that currently
available commercial serological assays recognize infection
with all five HIV-2 subtypes with comparable efficiency.
DISCUSSION
Identification of five distinct sequence subtypes of HIV-2.
The purpose of this study was to investigate the extent of
HIV-2 genetic diversity among 12 newly identified HIV-2
strains by direct analysis of viral sequences in uncultured
patient tissue and to examine their evolutionary relationships
by comparison to previously characterized HIV-2 and SIVsM/
SIVMAC sequences. PCR amplification of four independent
FIG. 3. Phylogenetic trees of HIV-2 subtypes derived from DNA sequences of partial gag (A), pol RT (B), pol integrase (int) (C), and env (D)
genes. Phylogenetic relationships were determined by the neighbor-joining method as described in Materials and Methods. Horizontal branch
lengths are drawn to scale, while vertical branches are for clarity only. The numbers on the nodes represent the percentage of bootstrap samples
with which the cluster to the right is supported; only those values greater than 80% are shown. The trees were rooted by using SIVMND as an
outgroup (65). Brackets denote individual sequence subtypes as described in Results. Newly characterized HIV-2 strains are boxed; viruses shown
in white on black failed to grow in tissue culture. Asterisks indicate previously published sequences from F0784 and 2238 (FO784pol.C12, M871 10;
2238pol.B7, M87138; FO784env.A13, M87069; 2238env.B10, M87118; and F0784RT.C2, M87111 [32]). Dynamically weighted parsimony methods
(95) yielded virtually identical trees (with respect to both topology and branch lengths).
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FIG. 4. Western blot profiles of sera from individ
the five sequence subtypes of HIV-2. Serum (or plasi
subjects FA (lane 1), 7924A (lane 2), 60415K (lane 3
60667K (lane 5), ON (lane 6), FT (lane 7), JA (lane E
2238 (lane 10), F0784 (lane 11), and PA (lane 12)
HIV-2 seroreactivity with the Cambridge Biotech HI
kit. Lanes + and -, positive and negative serum con
supplied by the manufacturer. Immunoreactive H]
indicated. Sera from individuals infected with virus
sequence subtype are grouped.
and nonoverlapping genomic regions allowed a
analysis of HIV-2 phylogeny and identified f
roughly equidistant genetic lineages which,
HIV-1, have been termed sequence subtypes,
Importantly, the majority of the newly identifi(
to replicate in tissue culture, and their moleci
tics would have gone unrecognized if sam
subjected to in vitro cultivation prior to seque
is customary for HIV-1 and HIV-2). Moreo
culture-negative viruses (PA) was found to difl
nucleotide sequence in the gag, pol, and en
previously reported HIV-2 strains, which apprc
of divergence observed between the two
HIV-1 (groups M and 0). These data thus ih
extent of HIV-2 genetic diversity is compar
HIV-1 and that multiple sequence subtypes
viruses. In contrast to HIV-1, however, tissue c
appears to be highly selective and to amplify
naturally occurring viruses. PCR amplificati
quences from primary patient material thus see
a more reliable method of screening for gen
HIV-2.
Geographic distribution of the various I
subtypes. The identification of five indepenc
eages also allowed an analysis of their preva
graphic distribution. Previous studies found n
relation between the geographic origin of an H
its phylogenetic clustering (8, 65). In partici
viruses were identified in many diverse loca
West Africa, including Senegal (ST and M
C D E Cape Verde Islands (ROD), Mali (BEN), Ghana (GH1), the
r-'"
'--" 11 Gambia (ISY and D194), and Guinea Bissau (NIHz, CAM2,10 11 12 and GB1222). Analyses of the 12 new viruses confirmed these
earlier observations, demonstrating in addition a lack of geo-
graphic clustering among HIV-2 strains representing sequence
qvijsubtypes B to E. The three newly identified subtype A viruses
came from individuals who originated from Ghana, Guinea
Bissau, and Senegal. The five new subtype B viruses were
derived from subjects most likely infected in Ghana, Cote
d'Ivoire, Sierra Leone, and possibly Nigeria (subject JA).
Finally, the single representatives of subtypes C (2238) and D
(FO784) were identified in Liberia (32), while the representa-
tive of subtype E (PA) likely came from Sierra Leone (43).
Thus, the origins of HIV-2 strains of different subtypes,
particularly those of members of the well-represented se-
- * quence subtypes A and B, overlapped considerably. This is
consistent with the finding of intersubtype recombinants (see
below), which require the presence and simultaneous spread of
divergent viral strains in the same population.
Simultaneous coinfection and viral recombination in HIV-
2-infected individuals. As shown in Fig. 3, the grouping of the
various HIV-2 strains into different sequence subtypes was
consistent across all four genomic regions analyzed. Neverthe-
less, there were two viruses which fell in different phylogenetic
luals infected with positions depending on which parts of their genomes were
ma) samples from compared (in both cases, the discordant branching orders were
N), 7312A (lane 4), supported by greater than 99% of bootstrap values and were
3), 7810A (lane 9), thus highly significant). Virus 7312A clustered with subtype B
were analyzed for viruses in the gag and pol (RT and integrase) regions but
[V-2 Western Blot grouped with subtype A viruses in the env tree. Since all 7312A
itrols, respectively, sequences were derived from the same proviral clone, these
IV-2 proteins are results indicate that it contains a mosaic genome and repre-
;es from the same sents a recombinant of viruses belonging to sequence subtypes
A and B. Similarly, FA fell into one subtype A subcluster in gag
and pol but grouped with a different subcluster in the env
region. This discordant branching may also be due to a mosaic
comprehensive (recombinant) genome or, alternatively, may indicate simulta-
ive distinct and neous coinfection of patient FA with two divergent subtype A
by analogy to viruses which were differentially amplified by the pol and env
A to E (Fig. 3). primer pairs. Cloning of a complete FA provirus will be
ed viruses failed necessary to distinguish between these two possibilities. Re-
ular characteris- gardless of which is the case, these examples document that
iples had been individuals can be coinfected with divergent HIV-2 strains.
nce analysis (as Although it is presently unknown how and under what
ver, one of the circumstances the same person becomes superinfected with
fer in 25% of its two different viruses, it is of interest that similar findings have
Iv regions from also been reported for HIV-1. One of the earliest character-
)aches the levels ized African strains (MAL [2]) contains a mosaic genome
iajor groups of comprising sequences from subtype D and A viruses (56, 82),
ndicate that the and more recently characterized isolates from Thailand might
-able to that of represent recombinants of viruses belonging to sequence sub-
exist for both types E and A (60, 82). These results thus indicate that
ulture of HIV-2 superinfection and recombination of phylogenetically distinct
only a subset of viruses can occur in both HIV-1- and HIV-2-infected individ-
ion of viral se- uals. Moreover, on the basis of our results with HIV-2, these
zms to represent events may happen relatively frequently (2 of 22 HIV-2 strains
ietic variants of in Fig. 3 exhibit a discordant branching order). Systematic
studies are needed to determine exactly how often and under
HIV-2 sequence what conditions individuals acquire genetically divergent
lent HIV-2 lin- HIV-1 or HIV-2 strains, since this information may be impor-
alence and geo- tant to current AIDS vaccine development efforts (particularly
to apparent cor- in Africa, where numerous HIV-1 and HIV-2 sequence sub-
[IV-2 isolate and types circulate in the same populations).
ular, subtype A Phylogenetic evidence for multiple introductions of geneti-
itions all across cally diverse sooty mangabey viruses into human and macaque
[VP-15132), the populations. In addition to defining new HIV-2 subtypes, the
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phylogenetic trees in Fig. 3 also shed new light on our
understanding of the origins and molecular evolution of the
entire HIV-2/SIVsM/SIVmAc group of viruses. For a number
of reasons, it is now believed that the common ancestor of this
group infected sooty mangabeys and that HIV-2 in humans
and SIVmAC in macaques are each the result of cross-species
transmissions. Most importantly, significant numbers (approx-
imately 30%) of sooty mangabeys are infected with SIVSM in
the wild (63). By contrast, SIVMAC has not been found in
wild-living Asian macaques but has been identified in four
different macaque species living in captivity (16, 48, 69). Also,
SIVSM is nonpathogenic in sooty mangabeys (29, 42, 64) but is
highly pathogenic in macaques (16, 48, 69), as is the case for
many zoonotic infections that cause less severe or no disease in
their natural host (87). From these findings, it thus seems clear
that SIVMAC was generated inadvertently by transfer of SIVSM
from naturally infected sooty mangabeys to macaques in the
setting of primate centers. Similarly, naturally infected sooty
mangabeys also represent the probable source of HIV-2 in the
human population. The natural habitat of sooty mangabeys
coincides with the geographic pattern of HIV-2 endemicity in
West Africa (32, 64), and in many West African countries,
mangabeys are hunted for food and kept as pets (63, 64). Thus,
scratches and bites of humans by monkeys and exposure to
monkey blood in the context of food preparation are common-
place. In addition, accidental transmission of an SIVsM strain
to a laboratory worker has recently demonstrated that humans
are susceptible to infection with sooty mangabey viruses (47).
Taken together, these observations strongly indicate that nat-
urally infected sooty mangabeys represent the reservoir for this
entire group of viruses.
The phylogenetic relationships of the various HIV-2, SIVSM,
and SIVmAc lineages shown in Fig. 3 thus suggest that sooty
mangabey viruses have entered both human and macaque
populations on more than one occasion. For example, the two
distinct and highly divergent clusters of SIVSTM (from stump-
tailed macaques) and SIVMAC/SIVMNE (from rhesus and
pig-tailed macaques) probably arose through independent
SIVSM transmission events. Assuming that the ancestral virus
(at the root at the left side of Fig. 3) infected sooty mangabeys,
then each of the HIV-2 lineages leading to PA, F0784, and the
A subtype must have similarly arisen from independent manga-
bey-to-human transfers. Moreover, the deep divergences of
2238 and subtype B viruses may also reflect independent
SIVSM transmissions. Then, a minimum of three and perhaps
as many as five instances (i.e., one for each sequence subtype)
of mangabey-to-human transmission are necessary to explain
the phylogeny of currently known HIV-2 sequences.
The conclusion that HIV-2 evolved as a result of cross-
species transmission from naturally infected sooty mangabeys
raises the questions of why all SIVSM isolates cluster within
only one of the five major lineages in Fig. 3 and why the
earliest-diverging branch is represented by a human virus
(PA). Although currently available sequence information is
still limited, there are several lines of evidence suggesting that
the genetic diversity of naturally occurring SIVSM strains is far
greater than presently appreciated. First, all but one of the SIV
sequences in Fig. 3 are derived from captive monkeys (ma-
caques and sooty mangabeys) housed in American primate
centers (the only "natural" SIV in the subtype D/SIV cluster is
SIVsMLIB, which was isolated from a Liberian pet sooty
mangabey [64]). It is thus likely that the SIV lineages defined
in Fig. 3 represent only a limited number of SIVSM introduc-
tions, possibly involving sooty mangabeys captured in the same
geographic area (interestingly, the human F0784 strain, which
clusters in the same group, also originated from Liberia [32]).
Second, all currently available SIVSM/SIVMAC sequences are
derived from viral isolates propagated in immortalized human
T-cell lines prior to molecular analysis. Given the obvious
selection biases of tissue culture with respect to HIV-2 isola-
tion (see below), it is quite possible that these SIV isolates also
represent only a subset of viruses inadvertently selected be-
cause of their in vitro growth characteristics. Finally, two
groups of investigators have recently reported phylogenetic
data for additional sooty mangabey strains which indicate that
they branch outside the subtype D/SIV cluster (11, 71). Taken
together, these findings suggest that there may be many more
SIVsM lineages than currently identified and that analysis of
wild-living sooty mangabeys and PCR amplification of uncul-
tured animal material will be necessary to determine the full
extent of their genetic diversity.
Subtype-specific differences in virus biology. Several previ-
ous studies noted lower isolation frequencies for HIV-2 than
for HIV-1 (1, 81, 83). Culturing virus from 20 HIV-2 seropos-
itive individuals from the Gambia, Schulz and coworkers
recovered only seven isolates (81). Similarly, Albert et al.
described lower isolation frequencies for HIV-2, particularly
from individuals with asymptomatic infection (1). Finally,
Simon and coworkers compared HIV-1 and HIV-2 isolation
frequencies systematically and reported a strong correlation
between HIV-2 recovery and clinical status (83). HIV-2 was
isolated from 100% of patients with CD4 counts below 200/pl
(10 of 10), from 62% of patients with CD4 counts between
200/pl and 500/1A (5 of 8), and from 18% of patients with CD4
counts above 500/,ul (4 of 22). By contrast, HIV-1 was isolated
from virtually all patients (52 of 54) at all stages of infection
(100, 94, and 92% recovery rates, respectively). In agreement
with these earlier studies, we also noted a markedly reduced
ability to culture HIV-2 from our patients. Only five HIV-2
isolates were obtained from the 12 seropositive subjects de-
spite repeated attempts in several independent laboratories.
However, the strongest predictor of in vitro viral growth in our
study was whether a virus was a member of a particular
sequence subtype. All subtype A viruses yielded positive
cultures regardless of whether they were derived from asymp-
tomatic individuals with high CD4 counts (60415K) or from
blood samples transported for extended periods of time (FA).
Even the recombinant 7312A virus, which contains a subtype A
env gene in the context of a subtype B genome (37), was
recovered on three independent occasions from an individual
with CD4 counts above 500 cells per mm3 (Tables 1 and 2). By
contrast, isolation frequencies from individuals infected with
subtype B to E viruses were significantly lower. Only one of five
subtype B viruses (60667K, from a patient with reduced CD4
counts) yielded a positive culture, despite the fact that two
additional individuals (ON and JA) with subtype B infections
suffered from end-stage AIDS. Finally, none of the single
representatives of sequence subtypes C, D, or E replicated in
vitro. This was the case despite several different isolation
strategies, particularly for subject PA, which included coculti-
vation with different target cells and depletion of patient CD8
cells, which have been reported to produce a factor(s) that
suppresses viral replication (91). These results thus suggest
differential abilities of members of the various HIV-2 subtypes
to grow under standard tissue culture conditions.
Simon and coworkers also reported a correlation between
HIV-2 isolation frequencies and virus load in infected individ-
uals (83). HIV-2-infected subjects with CD4 counts greater
than 200/pAl harbored considerably less virus (as determined by
limiting-dilution cultures as well as semiquantitative DNA
PCR) than did patients infected with HIV-1. It was thus
proposed that the ability of an HIV-2 strain to grow in vitro
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was also an indicator of its in vivo replication potential. Given
our finding of higher isolation frequencies for subtype A
viruses, the question arises of whether subtype A viruses grow
to higher titers in vivo as well as in vitro and thus exhibit a
more virulent phenotype. In this context, it is important to
point out that subtype A viruses are numerous and prevalent
throughout West Africa (65). Moreover, subtype A viruses are
the only HIV-2 strains that have been identified in large
numbers outside of West Africa (33). Several recent reports
indicate that they are spreading epidemically in India, where
they may be associated with accelerated disease (73, 77). Also,
sequences of subtype A viruses are the most common in the
database (65), which is an additional indicator of their wide
distribution, efficient transmission, and propensity to grow in
culture. In light of these data, it is tempting to speculate that
there are subtype-specific differences in HIV-2 biology and
that certain naturally occurring strains replicate to higher
titers, transmit more efficiently, and cause more virulent infec-
tions. Systematic natural history studies are needed to deter-
mine whether this is the case and whether there are subtype-
specific differences in HIV-2 pathogenicity. Also, the
mechanisms responsible for the observed in vitro differences,
which may include variation in cell tropism, potency of regu-
latory proteins, quasi-species complexity, proportion of defec-
tive viruses, or some combination of these factors, will have to
be elucidated. This information is crucial not only to ongoing
HIV drug and vaccine development efforts, but also for a
better understanding of the virologic mechanisms underlying
AIDS pathogenesis.
As important as evaluation of virulent HIV-2 strains will be
studies characterizing infections with viruses such as F0784,
2238, and PA. Their resistance to growth in tissue culture,
limited geographic distribution, and derivation from healthy
individuals and communities where HIV-2-associated AIDS
has not yet been recognized (32, 43) suggest relatively ineffi-
cient transmission and low pathogenic potential. As HIV-1-
infected persons are monitored over time, it has become
apparent that there are marked differences in the course of
their disease progression. Whereas the mean period to devel-
opment of symptomatic disease is approximately 10 years,
cohort studies have identified persons who have been infected
for up to 15 years with no evidence of CD4 decline (58). These
individuals are seropositive and contain HIV-1 sequences in
their blood cells but are generally virus isolation negative,
presumably because of a low viral burden. Subjects F0784,
2238, and PA described in this study mimic many of these
properties and could thus represent long-term survivors of
HIV-2. In particular, subject PA fits this description, since this
Sierra Leonean immigrant was infected with HIV-2 for prob-
ably 20 years (43) and never exhibited CD4 decline or any
other manifestation of HIV-2 disease (he eventually died of
causes unrelated to his HIV-2 infection). Also, it is clear that
lentiviral virulence properties are dictated by a complex inter-
play between both viral and host determinants and that
introduction of a virus into a new host species and serial
passage through members of the same species represent
contributing factors to disease progression. Given that some of
the various HIV-2 subtypes (e.g., F0784 and PA) have likely
resulted from independent transmissions of sooty mangabey
viruses, the question arises whether they differ in their level of
adaptation, and thus growth potential, in the human host.
Cohorts of individuals like subjects 2238, PA, and F0784
should be identified to establish the long-term effects of their
HIV-2 infections and to determine whether they harbor truly
attenuated viruses with reduced in vivo replication potential.
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